このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Hansa Biopharma 配当金

配当金基準チェック /06

Hansa Biopharma配当金を支払った記録がありません。

主要情報

n/a

配当利回り

n/a

配当性向

業界平均利回り	1.5%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
一株当たり利益	-SEK 11.82
配当利回り予想	0%

最近の配当金アップデート

更新なし

Recent updates

Investors Appear Satisfied With Hansa Biopharma AB (publ)'s (STO:HNSA) Prospects As Shares Rocket 28%

Aug 24

Hansa Biopharma AB (publ) (STO:HNSA) Analysts Just Slashed This Year's Revenue Estimates By 11%

Jul 23

Hansa Biopharma AB (publ) (STO:HNSA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Jul 21

Shareholders May Be Wary Of Increasing Hansa Biopharma AB (publ)'s (STO:HNSA) CEO Compensation Package

Jun 21

Hansa Biopharma AB (publ) (STO:HNSA) Looks Just Right With A 32% Price Jump

May 21

Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates

Apr 05

Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report

Feb 07

Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing

Dec 28

Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts

Oct 13

Hansa Biopharma AB (publ) (STO:HNSA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Feb 06

Need To Know: The Consensus Just Cut Its Hansa Biopharma AB (publ) (STO:HNSA) Estimates For 2023

Feb 01

決済の安定と成長

配当データの取得

安定した配当: HNSAの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: HNSAの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Hansa Biopharma 配当利回り対市場

HNSA 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (HNSA)	n/a
市場下位25% (SE)	1.5%
市場トップ25% (SE)	4.4%
業界平均 (Biotechs)	1.5%
アナリスト予想 (HNSA) (最長3年)	0%

注目すべき配当: HNSAは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: HNSAは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: HNSAの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: HNSAが配当金を報告していないため、配当金の持続可能性を計算できません。

Hansa Biopharma 配当金

配当金 基準チェック /06

主要情報

最近の配当金アップデート

Recent updates

Hansa Biopharma AB (publ) to Report Nine Months, 2025 Results on Oct 23, 2025

Investors Appear Satisfied With Hansa Biopharma AB (publ)'s (STO:HNSA) Prospects As Shares Rocket 28%

Matthew Shaulis, Chief Commercial Officer and US President Decides to Leave Hansa Biopharma AB in Late September

Hansa Biopharma AB (publ) (STO:HNSA) Analysts Just Slashed This Year's Revenue Estimates By 11%

Hansa Biopharma AB (publ) (STO:HNSA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

First quarter 2024 earnings released: kr4.15 loss per share (vs kr3.92 loss in 1Q 2023)

Consensus revenue estimates fall by 18%

Hansa Biopharma AB (publ) to Report Q1, 2025 Results on Apr 17, 2025

Hansa Biopharma AB (publ) Announces Board Appointments

Shareholders May Be Wary Of Increasing Hansa Biopharma AB (publ)'s (STO:HNSA) CEO Compensation Package

New minor risk - Share price stability

Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial

Hansa Biopharma AB (publ) (STO:HNSA) Looks Just Right With A 32% Price Jump

Price target decreased by 7.0% to kr103

Consensus revenue estimates increase by 17%

New minor risk - Shareholder dilution

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 372.1536 million.

Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates

Consensus revenue estimates decrease by 21%

Full year 2023 earnings: EPS exceeds analyst expectations

Hansa Biopharma AB (Publ) Announces CFO Changes

Consensus revenue estimates decrease by 16%, EPS upgraded

Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report

New minor risk - Profitability

No longer forecast to breakeven

New minor risk - Financial position

Full year 2023 earnings released: kr15.83 loss per share (vs kr13.60 loss in FY 2022)

Hansa Biopharma AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Forecast to breakeven in 2026

Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing

Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation

Hansa Biopharma Nomination Committee Formed

President & CEO recently bought kr115k worth of stock

Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Third quarter 2023 earnings: EPS misses analyst expectations

New minor risk - Profitability

Consensus revenue estimates fall by 17%

Price target decreased by 12% to kr148

Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts

New minor risk - Share price stability

Consensus revenue estimates decrease by 33%

Hansa Biopharma Provides Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma Announces Encouraging High-Level Results for First-In-Human Trial of HNSA-5487

Does Hansa Biopharma (STO:HNSA) Have A Healthy Balance Sheet?

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma, Effective 1 December 2023

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma

Consensus EPS estimates fall by 11%, revenue upgraded

Hansa Biopharma AB (publ) to Report Q1, 2024 Results on Apr 17, 2024

Hansa Biopharma Announces First Patient Treated with Imlifidase in an Investigator-Initiated Phase 2 Study in Anca-Associated Vasculitis

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Hansa Biopharma Receives Provisionally Approval in Australia as Desensitization Treatment in Highly Sensitized Patients Prior to Kidney Transplantation

Investors Holding Back On Hansa Biopharma AB (publ) (STO:HNSA)

Hansa Biopharma Announces First Patient Dosed with Imlifidase in a Global Pivotal Phase 3 Trial in Anti-Inaugular Basement Membrane (anti-GBM) Disease

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Rock star Growth Puts Hansa Biopharma (STO:HNSA) In A Position To Use Debt

Hansa Biopharma AB (publ) (STO:HNSA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 10%, revenue upgraded

Need To Know: The Consensus Just Cut Its Hansa Biopharma AB (publ) (STO:HNSA) Estimates For 2023

Hansa Biopharma Announces Planned Departure of Chief Scientific Officer Christian Kjellman

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma AB (publ) Announces Formation of Nomination Committee

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering.

Hansa Biopharma AB (Publ) Announces Positive Reimbursement Decision in Italy for Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Patients in Kidney Transplantation

Hansa Biopharma AB Announces Positive Topline Data from the Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Price target decreased to kr176

Hansa Biopharma AB and Partner Sarepta Therapeutics Plan to Initiate A Clinical Study with Imlifidase as A Pre-Treatment to Sarepta's SRP-9001 Gene Therapy in DMD in 2023

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Hansa Biopharma AB (publ) to Report First Half, 2023 Results on Jul 20, 2023

配当金基準チェック /06